Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.81 |
| ▸ | FLT3 | P36888 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | POLB | P06746 | 3/20 | 0.81 |
| ▸ | KIT | P10721 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.81 |
| ▸ | RELA | Q04206 | 1/20 | 0.81 |
| ▸ | MAOB | P27338 | 2/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.72 |
| ▸ | GABRP | O00591 | 3/20 | 0.72 |
| ▸ | GABRD | O14764 | 3/20 | 0.72 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.72 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504103 | 0.90 | FLT3 (0.81) | KMT2AFLT3MEN1MAPTNPC1 | |
| Pectolinarigenin SCHEMBL243686 | 0.90 | MAPT (1.00) | KMT2AFLT3MEN1MAPTNPC1 | |
| Pectolinarigenin SCHEMBL29606971 | 0.90 | MAPT (1.00) | KMT2AFLT3MEN1MAPTNPC1 | |
| SCHEMBL28732976 | 0.90 | FLT3 (0.81) | KMT2AFLT3MEN1MAPTNPC1 | |
| Ladanein SCHEMBL737069 | 0.88 | FLT3 (0.81) | KMT2AFLT3MEN1MAPTNPC1 | |
| SCHEMBL16521507 | 0.88 | MAPT (0.71) | KMT2AFLT3MEN1MAPTNPC1 | |
| Scutellarein SCHEMBL23854870 | 0.88 | KMT2A (0.89) | KMT2AFLT3MEN1MAPTNPC1 | |
| SCHEMBL28592818 | 0.88 | MAPT (0.74) | KMT2AFLT3MEN1MAPTNPC1 | |
| SCHEMBL10001096 | 0.86 | FLT3 (0.72) | KMT2AFLT3MEN1MAPTNPC1 | |
| SCHEMBL19303535 | 0.86 | FLT3 (0.69) | KMT2AFLT3MEN1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306317-A | Application of scutellarein methylated derivative in preparation of medicine for preventing and/or treating novel coronavirus | 复旦大学 | 2022-04-12 | — | — | CN | claimed |
| WO-2005020881-A2 | COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES | SHANGHAI COMMAN PHARMACEUTICAL CO. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | claimed |
| EP-4580594-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | AnalytiCon Discovery - Zweigniederlassung der BRAIN Biotech AG (DE) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024046834-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-03-07 | — | — | WO | disclosed |
| EP-4331564-A1 | ANTIOXIDANT COMPOSITION COMPRISING 5-DEOXYFLAVONOIDS | Analyticon Discovery GmbH (DE) | 2024-03-06 | — | — | EP | disclosed |
| CN-114306317-A | Application of scutellarein methylated derivative in preparation of medicine for preventing and/or treating novel coronavirus | 复旦大学 | 2022-04-12 | — | — | CN | disclosed |
| US-10744114-B2 | Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | OSTEONEUROGEN INC. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-10744113-B2 | Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | OSTEONEUROGEN INC. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-20190231739-A1 | NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2019-08-01 | — | — | US | disclosed |
| EP-2868657-B1 | METHOD FOR PREPARING HIGH PURITY SCUTELLARIN AGLYCONE | KPC PHARMACEUTICALS INC (CN) | 2017-08-30 | — | — | EP | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231739-A1 | NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | KMT2A 3011/4885FLT3 4672/4885MEN1 2220/4885 |
| US-10744113-B2 | Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | CDH1, SMAD3, SMAD2 | KMT2A 2795/4885FLT3 4706/4885MEN1 1939/4885 |
| US-20050049206-A1 | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases | FNTA, COLGALT1, F3 | KMT2A 4107/4885FLT3 4440/4885MEN1 4807/4885 |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | KMT2A 2795/4885FLT3 4706/4885MEN1 1939/4885 |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | HTR2C, GRIN2C, HTR5A | KMT2A 1058/4885FLT3 3391/4885MEN1 4859/4885 |
| US-10744114-B2 | Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | SMAD2, CDH1, SMAD3 | KMT2A 3821/4885FLT3 4853/4885MEN1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.